Nuevolution Forms Drug Discovery Pact With J&J

Nuevolution A/S has entered into collaboration with Janssen Biotech Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, using Nuevolution’s proprietary Chemetics drug discovery platform. The collaboration was facilitated by Johnson & Johnson Innovation, in partnership with Janssen Discovery Sciences.

Nuevolution, a privately held Copenhagen-based biotechnology company is applying its propriety drug discovery platform to the generation of novel small molecule therapeutics. The collaboration will focus on the discovery and development of new medical entities for the treatment of oncological, infectious and inflammatory diseases.

Within the framework of the collaboration, Nuevolution will apply its drug discovery platform Chemetics to discover and advance drug candidates against drug targets of interest to Janssen. Under the terms of the agreement, Nuevolution will receive an upfront payment, research funding and would be eligible to milestone payments upon achievement of specified research, development and commercial milestones. In addition, Nuevolution would be entitled to receive certain royalty payments on net-sale of products that may be commercialized as a result of the collaboration.